Courtney Lamm
Primary Care · Milwaukee, WINPI 1376185819
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 37.9% of the total. Reporting peaked in 2021 at $1,303 and has fallen 79.7% since, to $264 in 2023.
Across 89 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$652
- Daiichi Sankyo Inc.$447
- AstraZeneca$235
- Novo Nordisk$60
- Boehringer Ingelheim$57
- GSK$47
- plus $222 from 9 others
What the payments were for
- Food & beverage$1,721100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $652 |
| Daiichi Sankyo Inc. | 14 | $447 |
| AstraZeneca | 8 | $235 |
| Novo Nordisk | 4 | $60 |
| Boehringer Ingelheim | 4 | $57 |
| GSK | 3 | $47 |
| Agile Therapeutics, Inc. | 3 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Pfizer | 1 | $33 |
| Lilly USA, LLC | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| USWM, LLC | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- INJECTAFER$124
How this compares
$1,721 in reported general payments places this provider in the 85th percentile of 52 primary care providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 149 | $78,565 |
| XareltoRivaroxaban | 18 | $13,216 |
| LumiganBimatoprost | 14 | $3,728 |
| Duloxetine Hcl | 52 | $2,937 |
| Gabapentin | 143 | $2,755 |
| Midodrine Hcl | 27 | $2,719 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,703 |
| Metoprolol Succinate | 144 | $2,557 |
| Atorvastatin Calcium | 170 | $2,475 |
| Potassium Chloride | 134 | $2,449 |
| Memantine Hcl ErMemantine Hcl | 12 | $2,276 |
| Pantoprazole Sodium | 119 | $1,913 |
| Levothyroxine Sodium | 139 | $1,908 |
| Bumetanide | 49 | $1,667 |
| Amlodipine Besylate | 168 | $1,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $78,565149 claims |
| Johnson & JohnsonXarelto | $13 | $13,21618 claims |
| AbbVieLumigan | $652 | $3,72814 claims |
| AstraZenecaSymbicort | $235 | $2,70311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 52 primary care providers in Wisconsin.
Other primary care in Milwaukee
- Michael PotnekMilwaukee$71K
- Kelly StoneMilwaukee$2K
- Mary WiseMilwaukee$2K
- Alexandra KochMilwaukee$525
- Jana ZullnerMilwaukee$461
- Lisa KorbanMilwaukee$301
- Heejin KwonMilwaukee$267
- Lauren NewellMilwaukee$243
- Cheryl GatesMilwaukee$120
- Blanca BobadillaMilwaukee$107
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.